Amarin Reports Second Quarter 2019 Financial Results and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amarin Corp. (AMRN) Tops Q2 EPS by 4c, Revenues Beat
July 31, 2019 5:44 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $100.8 million versus the consensus estimate of $99.54 million.
Record Total Revenue of $100.8 Million Achieved in Q2 2019Commercial Expansion Plans on Track in Anticipation of September 28, 2019 PDUFA Date for Vascepa®If Approved, Vascepa to Become First Prescription Therapy to Treat Patients with Underlying Cardiovascular Risk Beyond Cholesterol Management as Demonstrated in the REDUCE-IT Cardiovascular Outcomes StudyMillions of Patients in the U.S. Have Underlying Cardiovascular Risk Beyond Cholesterol... More